Position
SYNTAX RESEARCH, INC. in Regeneron Pharmaceuticals, Inc.
Back to the book · All holders of REGN
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $188$771.87 → $772.64
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 245 | $189.1K | — | — | — | 0.1% |
| Q1 2026 | 245 | $189.3K | $772.64 | $188 | −$0 | 0.1% |